Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Phase 1/2 Recruiting
92 enrolled
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
442 enrolled
REACH
Phase NA Recruiting
257 enrolled
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Phase 1 Recruiting
134 enrolled
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Phase 1 Recruiting
51 enrolled
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
Phase 2 Recruiting
40 enrolled
Obeticholic Acid for Prevention in Barrett's Esophagus
Phase 2 Recruiting
30 enrolled
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Phase 1/2 Recruiting
49 enrolled
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Phase 1 Recruiting
42 enrolled
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
Phase 1 Recruiting
18 enrolled
SUR-CAN
Phase 2 Recruiting
88 enrolled
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
Phase 1 Recruiting
36 enrolled
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
Phase 1 Recruiting
43 enrolled
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Phase 1 Recruiting
24 enrolled
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Phase 1/2 Recruiting
58 enrolled
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2 Recruiting
163 enrolled
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Phase 1 Recruiting
30 enrolled
SCOTI
Phase 2 Recruiting
50 enrolled
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
290 enrolled
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
Phase 1 Recruiting
30 enrolled
PROSPER
Phase 1/2 Recruiting
403 enrolled
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Phase 1/2 Recruiting
768 enrolled
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
140 enrolled
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Phase 1 Recruiting
514 enrolled
Retrolaminar Block Versus Subcostal Transversus Abdominis Plane Block in Liver Resection Surgery
Phase NA Recruiting
90 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer
Phase NA Recruiting
30 enrolled
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
Phase 1 Recruiting
39 enrolled
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
Phase 1 Recruiting
24 enrolled
Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0)
Phase NA Recruiting
60 enrolled
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
Phase 1/2 Recruiting
92 enrolled
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 Recruiting
387 enrolled
The Vanguard Study: Testing a New Way to Screen for Cancer
Phase NA Recruiting
24,000 enrolled
IAPETUS
Phase 2 Recruiting
33 enrolled
DUAL-NK-PDAC
Phase 1/2 Recruiting
42 enrolled
A Study of KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy as First-line Treatment in Patients With Advanced Esophageal Cancer
Phase 2 Recruiting
60 enrolled
A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer
Phase 1 Recruiting
12 enrolled
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Phase 1/2 Recruiting
27 enrolled
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Phase 2 Recruiting
327 enrolled
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Phase 2 Recruiting
172 enrolled
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Phase 2/3 Recruiting
224 enrolled
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer
Phase 1 Recruiting
15 enrolled
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Phase 1 Recruiting
135 enrolled
Study for AZD4360 in Participants With Advanced Solid Tumours
Phase 1/2 Recruiting
117 enrolled
ADVICE
Phase 1/2 Recruiting
80 enrolled
SERENTA
Phase 3 Recruiting
168 enrolled
FRUITION
Phase 2 Recruiting
120 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
AB02
Phase 3 Recruiting
1,100 enrolled
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Phase 2/3 Recruiting
990 enrolled